FY 2025 Results
Ipsen’s financial results for the full year 2025 will be published on 12 February 2026.
An investor and analyst conference call will take place on the same day.
Period
recent search
Showing: 1 – 05 of 32 Financial Results
11 February 2021
LinkedIn
Facebook
22 October 2020
LinkedIn
Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance
Paris (France), 22 October 2020 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2020.
30 July 2020
LinkedIn
Ipsen presents its half year 2020 results and reinstates guidance for full year 2020
David Loew, Chief Executive Officer of Ipsen, stated: “I’m honored since July 1st to lead Ipsen, an exciting global biopharma business with solid business fundamentals, a strong purpose to serve patients and attractive growth opportunities. I am encouraged by the exceptional levels…
22 April 2020
LinkedIn
Ipsen reports solid sales growth in first quarter 2020 with limited COVID-19 impact
Paris (France), 22 April 2020 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its sales for the first quarter of 2020.
13 February 2020
LinkedIn
Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook
Aymeric Le Chatelier, Chief Executive Officer and Chief Financial Officer of Ipsen, stated: “2019 was another excellent year of operating performance for Ipsen with continued double-digit top-line growth and core operating margin expansion. Despite the recent palovarotene setback, the fundamentals of…
Your dedicated contacts
Henry Wheeler
Vice President, Investor Relations
Khalid Deojee
Senior Manager, Investor Relations